Unique ID issued by UMIN | UMIN000059262 |
---|---|
Receipt number | R000067760 |
Scientific Title | Efficacy of 12-week continuous application lipids derived from animal at two dosage levels on scalp barrier function: a randomized, single-blind trial |
Date of disclosure of the study information | 2025/10/06 |
Last modified on | 2025/09/30 18:21:56 |
Efficacy of 12-week continuous application lipids derived from animal at two dosage levels on scalp barrier function
Efficacy of 12-week continuous application lipids derived from animal at two dosage levels on scalp barrier function
Efficacy of 12-week continuous application lipids derived from animal at two dosage levels on scalp barrier function: a randomized, single-blind trial
Efficacy of 12-week continuous application lipids derived from animal at two dosage levels on scalp barrier function
Japan |
no
Not applicable | Adult |
Others
NO
To evaluate the efficacy of 12-week application of the test sample on scalp barrier function and subjective questionnaire assessments related to scalp dryness.
Efficacy
Confirmatory
Pragmatic
Not applicable
Comparison of changes in TEWL across subjects at each assessment week
Comparison of actual TEWL measurements among individual subjects at each assessment week
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
No treatment
Institution is not considered as adjustment factor.
YES
2
Educational,Counseling,Training
Other |
Duration: one week
0.001% lipids derived from animal Solution
Duration: one week
0.01% lipids derived from animal solution
20 | years-old | <= |
Not applicable |
Male and Female
1. Japanese
2. Men or women
3. Adults
4. Healthy individuals
5. Individuals who are concerned about scalp dryness in daily life
1. Individuals currently receiving medication or outpatient treatment for any serious medical condition
2. Individuals who are undergoing exercise or alimentary therapy under medical supervision
3. Individuals with skin or scalp conditions, including atopic dermatitis, contact dermatitis, skin hypersensitivity, or scalp redness and itchiness
4. Individuals with allergic diseases, including egg allergy
5. Individuals with extremely irregular lifestyle habits, such as diet or sleep
6. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study
13
1st name | Yusuke |
Middle name | |
Last name | Yamashita |
Pharma Foods International Co., Ltd.
R&D Department
615-8245
1-49, Goryo Ohara, Nishikyo-ku, Kyoto, Japan
075-748-9829
Kayoko-yamaguchi@pharmafoods.co.jp
1st name | Kayoko |
Middle name | |
Last name | Yamaguchi |
Pharma Foods International Co., Ltd.
R&D Department
615-8245
1-49, Goryo Ohara, Nishikyo-ku, Kyoto, Japan
075-748-9829
Kayoko-yamaguchi@pharmafoods.co.jp
Pharma Foods International Co.,Ltd
Pharma Foods International Co., Ltd.
Profit organization
The ethical committee of the Shiba Palace Clinic
6F Daiwa A Hamamatsucho, 1-9-10 Hamamatsucho, Minato-ku, Tokyo, Japan
03-5408-1590
jimukyoku@mail.soken-r.com
NO
株式会社ファーマフーズ
Pharma Foods International Co., Ltd. (Kyoto, Japan)
2025 | Year | 10 | Month | 06 | Day |
Unpublished
Preinitiation
2025 | Year | 10 | Month | 06 | Day |
2025 | Year | 10 | Month | 06 | Day |
2025 | Year | 12 | Month | 26 | Day |
2025 | Year | 10 | Month | 01 | Day |
2025 | Year | 09 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067760